Allergan Inc. - Special Call

Allergan Inc. (AGN)

March 28, 2012 1:00 pm ET


Unknown Executive -

Scott M. Whitcup - Chief Scientific Officer and Executive Vice President of Research & Development

David E.I. Pyott - Chairman, Chief Executive officer and President

Mitchell Brin -

Frederick Beddingfield -

Gregory H. Altman - Founder, Chief Executive Officer, President and Director


David Risinger - Morgan Stanley, Research Division

David Amsellem - Piper Jaffray Companies, Research Division

Aaron Gal - Sanford C. Bernstein & Co., LLC., Research Division

Shibani Malhotra - RBC Capital Markets, LLC, Research Division

Douglas D. Tsao - Barclays Capital, Research Division

John T. Boris - Citigroup Inc, Research Division

Gary Nachman - Susquehanna Financial Group, LLLP, Research Division

Catherine J. Arnold - Crédit Suisse AG, Research Division

Unknown Analyst

Seamus Fernandez - Leerink Swann LLC, Research Division

David G. Buck - The Buckingham Research Group Incorporated

Christopher Schott - JP Morgan Chase & Co, Research Division

Gregory B. Gilbert - BofA Merrill Lynch, Research Division

Annabel Samimy - Stifel, Nicolaus & Co., Inc., Research Division

Larry Biegelsen - Wells Fargo Securities, LLC, Research Division

Gregory Waterman - Goldman Sachs Group Inc., Research Division


Unknown Executive

So I wanted to welcome everyone to the 2012 R&D Technology Review. Just find your seats. And with that, I'd like to introduce Dr. Scott Whitcup.

Scott M. Whitcup

Well, thank you, Jim, and I want to thank everyone for coming out to our R&D Technology Review. As you know, what we try to do in these is give you insight into some of the pipeline that some of you haven't seen before and some balance. We'll have some updates on late-stage programs, but importantly give you some look at early-stage science as well.

I want to start by introducing myself. I'm Scott Whitcup, I'm the Executive Vice President of R&D and Chief Scientific Officer and lead the group on Pharma and Medical Device side and want to start off by thanking the vast number of scientists and clinical developers who really did all the work on the science and clinical trials that we present today, and also a thanks to the IR staff, especially Joann Bradley and David Nakasone who really helped organize this.

If you liked this article you might like

Elizabeth Warren Slams Wells Fargo, Equifax: Cramer's Top Takeaways

Centene: Cramer's Top Takeaways

The Pitney Bowes Transformation: Cramer's Top Takeaways

Healthcare Trust of America, Marathon Petroleum: 'Mad Money' Lightning Round

How Long Can This Rally Run?: Cramer's 'Mad Money' Recap (Monday 9/19/17)